Senexin B

Senexin B (SNX2-1-165; BCD-115) is a potent, highly water-soluble and bioavailable CDK8/19 inhibitor, with Kds of 140 nM for CDK8 and 80 nM for CDK19.

Product Specifications

CAS Number

[1449228-40-3]

Product Name Alternative

SNX2-1-165; BCD-115

UNSPSC

12352005

Hazard Statement

H302, H315, H319, H335

Target

CDK

Type

Reference compound

Related Pathways

Cell Cycle/DNA Damage

Applications

Cancer-Kinase/protease

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/Senexin_B.html

Purity

99.09

Solubility

DMSO : 6 mg/mL (ultrasonic; warming) |H2O : < 0.1 mg/mL

Smiles

N#CC1=CC2=C(NCCC3=CC=C4C=C(C(N5CCN(C)CC5)=O)C=CC4=C3)N=CN=C2C=C1

Molecular Formula

C27H26N6O

Molecular Weight

450.53

Precautions

H302, H315, H319, H335

References & Citations

[1]Porter D, et al. Abstract PR08: Targeting tumor microenvironment with selective small-molecule inhibitors of CDK8/19. Abstracts: AACR Special Conference on Cellular Heterogeneity in the Tumor Microenvironment; 2014 Feb 26-Mar 1; San Diego, CA. Philadelphia (PA) : AACR; Cancer Res 2015;75 (1 Suppl) :Abstract nr PR08. doi:10.1158/1538-7445.CHTME14-PR08|[2]McDermott MS, et al. Inhibition of CDK8 mediator kinase suppresses estrogen dependent transcription and the growth of estrogen receptor positive breast cancer. Oncotarget. 2017 Feb 21;8 (8) :12558-12575.|[3]CDK8-CDK19 selective inhibitors and their use in anti-metastatic and chemopreventative methods for cancer. US 9321737 B2